Article
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.
Antimicrobial agents and chemotherapy - 1 Oct 2001
Barditch-Crovo P, Deeks S G, Collier A, Safrin S, Coakley D F, Miller M, Kearney B P, Coleman R L, Lamy P D, Kahn J O, McGowan I, Lietman P S
Abstract excerpt
Tenofovir DF is an antiviral nucleotide with activity against human immunodeficiency virus type 1 (HIV-1). The pharmacokinetics, safety, and activity of oral tenofovir DF in HIV-1-infected adults were evaluated in a randomized, double-blind, placebo-controlled, escalating-dose study of four doses (75, 150, 300, and 600 mg given once daily). Subjects received a single dose of tenofovir DF or a placebo, followed by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.